Pursue Wealth Partners LLC Purchases New Holdings in Axon Enterprise, Inc (NASDAQ:AXON)

Pursue Wealth Partners LLC bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 9,543 shares of the biotechnology company's stock, valued at approximately $5,019,000. Axon Enterprise makes up 3.0% of Pursue Wealth Partners LLC's investment portfolio, making the stock its 7th biggest holding.

A number of other institutional investors also recently bought and sold shares of the company. Pinion Investment Advisors LLC lifted its position in shares of Axon Enterprise by 3.0% in the first quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company's stock valued at $341,000 after acquiring an additional 19 shares in the last quarter. Kentucky Retirement Systems lifted its position in shares of Axon Enterprise by 0.4% in the first quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company's stock valued at $2,605,000 after acquiring an additional 19 shares in the last quarter. Beacon Pointe Advisors LLC lifted its position in shares of Axon Enterprise by 2.6% in the fourth quarter. Beacon Pointe Advisors LLC now owns 864 shares of the biotechnology company's stock valued at $513,000 after acquiring an additional 22 shares in the last quarter. Transcend Capital Advisors LLC lifted its position in shares of Axon Enterprise by 3.6% in the fourth quarter. Transcend Capital Advisors LLC now owns 726 shares of the biotechnology company's stock valued at $431,000 after acquiring an additional 25 shares in the last quarter. Finally, Fielder Capital Group LLC lifted its position in shares of Axon Enterprise by 2.2% in the fourth quarter. Fielder Capital Group LLC now owns 1,176 shares of the biotechnology company's stock valued at $699,000 after acquiring an additional 25 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Trading Up 2.4%

NASDAQ:AXON traded up $18.88 on Thursday, hitting $803.95. 484,248 shares of the stock were exchanged, compared to its average volume of 543,030. The stock has a market cap of $62.59 billion, a PE ratio of 194.19, a PEG ratio of 90.37 and a beta of 1.29. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68. The stock has a fifty day moving average of $709.79 and a 200-day moving average of $629.30. Axon Enterprise, Inc has a fifty-two week low of $279.02 and a fifty-two week high of $806.64.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. The company had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm's revenue was up 31.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.15 earnings per share. As a group, equities analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Brittany Bagley sold 3,400 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total value of $2,380,000.00. Following the completion of the sale, the chief financial officer now owns 131,833 shares in the company, valued at approximately $92,283,100. This trade represents a 2.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the sale, the chief executive officer now owns 3,063,982 shares of the company's stock, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,642 shares of company stock worth $30,500,428 over the last three months. 4.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on AXON. Barclays upped their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Needham & Company LLC increased their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Bank of America increased their target price on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. The Goldman Sachs Group increased their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Finally, Craig Hallum downgraded Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $699.55.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.